New secondary metabolites of phenylbutyrate in humans and rats.

Phenylbutyrate is used to treat inborn errors of ureagenesis, malignancies, cystic fibrosis, and thalassemia. High-dose phenylbutyrate therapy results in toxicity, the mechanism of which is unexplained. The known metabolites of phenylbutyrate are phenylacetate, phenylacetylglutamine, and phenylbutyrylglutamine. These are excreted in urine, accounting for a variable fraction of the dose. We identified new metabolites of phenylbutyrate in urine of normal humans and in perfused rat livers. These metabolites result from interference between the metabolism of phenylbutyrate and that of carbohydrates and lipids. The new metabolites fall into two categories, glucuronides and phenylbutyrate beta-oxidation side products. Two questions are raised by these data. First, is the nitrogen-excreting potential of phenylbutyrate diminished by ingestion of carbohydrates or lipids? Second, does competition between the metabolism of phenylbutyrate, carbohydrates, and lipids alter the profile of phenylbutyrate metabolites? Finally, we synthesized glycerol esters of phenylbutyrate. These are partially bioavailable in rats and could be used to administer large doses of phenylbutyrate in a sodium-free, noncaustic form.

[1]  M. Boyle,et al.  Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  D. Kerr,et al.  Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. , 2002, Journal of mass spectrometry : JMS.

[3]  M. Grever,et al.  Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  L. Grochow,et al.  A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  L. Grochow,et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Zeitlin,et al.  Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. , 2000, American journal of physiology. Cell physiology.

[7]  M. Pierce,et al.  Enantioselective synthesis of β-hydroxy carboxylic acids: direct conversion of β-oxocarboxylic acids to enantiomerically enriched β-hydroxy carboxylic acids via neighboring group control , 1999 .

[8]  A. Cho,et al.  Major role of the CYP2C isozymes in deamination of amphetamine and benzphetamine: evidence for the quinidine-specific inhibition of the reactions catalysed by rabbit enzyme. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  M. Beylot,et al.  Noninvasive probing of citric acid cycle intermediates in primate liver with phenylacetylglutamine. , 1996, The American journal of physiology.

[10]  D. Samid,et al.  Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine , 1995, Journal of clinical pharmacology.

[11]  H. Brunengraber,et al.  Metabolism of R-beta-hydroxypentanoate and of beta-ketopentanoate in conscious dogs. , 1995, The American journal of physiology.

[12]  H. Brunengraber,et al.  Assay of the enantiomers of 1,2-propanediol, 1,3-butanediol, 1,3-pentanediol, and the corresponding hydroxyacids by gas chromatography-mass spectrometry. , 1994, Analytical biochemistry.

[13]  S. Roelens,et al.  A protocol for the efficient synthesis of enantiopure .beta.-substituted .beta.-lactones , 1993 .

[14]  J. Wahren,et al.  Noninvasive tracing of Krebs cycle metabolism in liver. , 1991, The Journal of biological chemistry.

[15]  A. Conney,et al.  Effects of protein and carbohydrate content of diet on drug conjugation , 1991, Clinical pharmacology and therapeutics.

[16]  S. Brusilow.  Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion , 1991, Pediatric Research.

[17]  H. Kalant,et al.  Principles of Medical Pharmacology , 1989 .

[18]  H. Brunengraber,et al.  Interference of 3-hydroxyisobutyrate with measurements of ketone body concentration and isotopic enrichment by gas chromatography-mass spectrometry. , 1988, Analytical biochemistry.

[19]  S. Robins,et al.  Origin of biliary cholesterol and lecithin in the rat: contribution of new synthesis and preformed hepatic stores. , 1982, Journal of lipid research.

[20]  S. Brusilow,et al.  New approaches to the diagnosis and treatment of inborn errors or urea synthesis. , 1981, Pediatrics.

[21]  G. Jones,et al.  The effects of cofactor and species differences on the in vitro metabolism of propiophenone and phenylacetone. , 1981, Canadian journal of physiology and pharmacology.

[22]  H. Ramsdell,et al.  Gas chromatographic studies of twenty metabolically important acylglycines. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[23]  J. Strong,et al.  Identification of separate acyl- CoA:glycine and acyl-CoA:L-glutamine N-acyltransferase activities in mitochondrial fractions from liver of rhesus monkey and man. , 1976, The Journal of biological chemistry.

[24]  M. James,et al.  The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species , 1972, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[25]  K. Pedersen.  THE KETONIC DECOMPOSITION OF BETA-KETO CARBOXYLIC ACIDS , 1929 .

[26]  M. Tuchman,et al.  Alternative pathway therapy for urea cycle disorders: twenty years later. , 2001, The Journal of pediatrics.

[27]  M. R. Lee,et al.  Determination of pyrolysis products of smoked methamphetamine mixed with tobacco by tandem mass spectrometry. , 1999, Journal of analytical toxicology.

[28]  S. Shack,et al.  Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. , 1997, Advances in experimental medicine and biology.

[29]  S. Brusilow,et al.  Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. , 1994, Blood.

[30]  J. Lowenstein,et al.  Fatty Acid, 3‐β‐Hydroxysterol, and Ketone Synthesis in the Perfused Rat Liver , 1978 .

[31]  J. Lowenstein,et al.  Use of the perfused liver for the study of lipogenesis. , 1975, Methods in enzymology.

[32]  A. Dreiding,et al.  Thermische Lactonisierung von Estern γ-Brom-α, β-ungesättigter Carbonsäuren zu Δα-Butenoliden. Direkte γ-Bromierung von α, β-ungesättigten Säuren , 1970 .

[33]  Franz Knoop,et al.  Der Abbau aromatischer Fettsäuren im Tierkörper , 1904 .